Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of Hunner lesion in interstitial cystitis/bladder pain syndrome patients. To analyze the number and timing of recurrence based on a long-term follow-up.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hyaluronic Acid and Chondroitin Sulfate | Experimental | Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hyaluronic Acid and Chondroitin Sulfate | Drug | Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients. |
| Measure | Description | Time Frame |
|---|---|---|
| change in recurrence rate in Hyaluronic Acid and Chondroitin Sulfate instillation group after transurethral resection treatment | Every 3 months for 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| changes in mean number of daytime frequency episodes | Every 3 months for 2 years | |
| changes in mean number of nocturia episodes | Every 3 months for 2 years | |
| changes in mean number of urgency episodes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Samsung Medical Center, Sungkyunkwan University School of Medicine | Seoul | 135-710 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Every 3 months for 2 years |
| Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) | Every 3 months for 2 years |
| Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF) | Every 3 months for 2 years |
| Score of Global Response Assessment (GRA) | Every 3 months for 2 years |
| Patient Global Assessment | at the end of the treatment(2 years) |
| Occurrence of adverse event | Every 3 months for 2 years |
| ID | Term |
|---|---|
| D018856 | Cystitis, Interstitial |
| ID | Term |
|---|---|
| D003556 | Cystitis |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D006820 | Hyaluronic Acid |
| D002809 | Chondroitin Sulfates |
| ID | Term |
|---|---|
| D006025 | Glycosaminoglycans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
| D002807 | Chondroitin |
Not provided
Not provided